fashion -WSS

fashion

author：explore 2025-09-06 03:33:49 - browse：32527

Stock exchange — Drew Angerer/Getty Images

Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two small studies, leading shares to surge in pre-market trading.

In a 12-week Phase 2a study, the daily pill in a capsule formulation led to 6.2% placebo-adjusted weight loss. In a separate 12-week pharmacokinetics study, the company tested a new tablet formulation of the drug, called GSBR-1290, and it led to placebo-adjusted weight loss of up to 6.9%.

Though it’s difficult to compare across different studies, the results appear to approach the levels of weight loss seen at 12 weeks in a separate Phase 2 study of Eli Lilly’s GLP-1 pill called orforglipron. That entire study lasted 36 weeks, but at 12 weeks, participants had about 6%-7% placebo-adjusted weight loss.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Why do women spend more than men on medical expenses?

explore

WSS

Novo Nordisk to expand supply of Wegovy for U.S. patients

A $475,000 price tag for a new cancer drug: crazy or meh?

Inequities make cancer less preventable for women: report

Covid misinformation case heads to Supreme Court

Did you have Obamacare on your GOP debate bingo card?

Biden administration opens offers in Medicare drug price negotiations

explore

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

The high cost of giving birth even with insurance

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Menendez indictment could see pharma lose a key ally

Duchenne breakthrough therapy leaves behind pioneering families

Cigna to pay $172 million to settle Medicare Advantage fraud probe

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Mindstrong's demise and the future of mental health care

Guidelines to prevent youth baseball injuries need more muscle

Do digital therapeutics have a future in medicine?

leisure time

Would Medicare drug price negotiations stall in a shutdown?

STAT Virtual Event: How to Increase Diversity in Clinical Trials

Inequities make cancer less preventable for women: report

Vertigo drug brings hope for rare neuron disorder, Niemann

Covid misinformation case heads to Supreme Court

Juul spent big to court Black leaders to promote its e

explore

explore

entertainment

Wikipedia